Product image of Metformina + Sitagliptina Blixie (Metformin Hydrochloride, Sitagliptin) supplied by GNH India

Metformina + Sitagliptina Blixie

Active Ingredient:
Metformin Hydrochloride, Sitagliptin
Origin:
EU

Metformina + Sitagliptina Blixie (Metformin Hydrochloride, Sitagliptin)

Metformin Hydrochloride and Sitagliptin, the active ingredients in Metformina + Sitagliptina Blixie, are a Biguanide and DPP‑4 inhibitor combination presented as an oral tablet for systemic use. They are employed to improve glycemic control in adults with type 2 diabetes mellitus by reducing hepatic glucose production and enhancing insulin secretion.

GNH India supplies Metformina + Sitagliptina Blixie as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to stringent quality standards and regulatory requirements to ensure product integrity.

Manufacturer / TM Owner

Farmoz - Sociedade Técnico Medicinal, S.A.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Metformina + Sitagliptina Blixie is used in the management of type 2 diabetes mellitus, acting on multiple glucose‑regulating pathways.

  • Type 2 diabetes mellitus (inadequate control with metformin alone): provides additional HbA1c reduction when added to diet and exercise.
  • Type 2 diabetes mellitus (as initial therapy when metformin is contraindicated): offers glucose‑lowering effect via complementary mechanisms.
  • Type 2 diabetes mellitus (as adjunct to other antidiabetic agents): enhances overall glycemic control in combination regimens.

How It Works

  • Metformin decreases hepatic gluconeogenesis and improves peripheral insulin sensitivity, while sitagliptin inhibits the dipeptidyl peptidase‑4 enzyme, prolonging the activity of endogenous incretin hormones (GLP‑1 and GIP). The combined actions increase glucose‑dependent insulin secretion, suppress glucagon release, and reduce post‑prandial glucose excursions.

Side Effects

Metformina + Sitagliptina Blixie may cause a range of adverse reactions. Patients should be aware of both common and serious possibilities.

Common Side Effects

  • Nausea: mild to moderate stomach upset.
  • Diarrhea: loose stools, often transient.
  • Abdominal discomfort: cramping or pain.
  • Headache: mild tension‑type headache.
  • Upper respiratory tract infection: cold‑like symptoms.
  • Fatigue: general tiredness.

Serious or Rare Side Effects

  • Lactic acidosis: rare but life‑threatening metabolic disturbance.
  • Severe hypoglycemia: especially when combined with insulin or sulfonylureas.
  • Pancreatitis: acute inflammation of the pancreas.
  • Hepatic dysfunction: abnormal liver enzymes.
  • Skin reactions: rash or hypersensitivity.
  • Renal impairment worsening: decline in kidney function.

Precautions & Warnings

Before initiating therapy, clinicians should evaluate patient‑specific factors and monitor for potential complications.

  • Renal function assessment: evaluate eGFR and avoid use in severe renal impairment.
  • Lactic acidosis risk: contraindicated in patients with conditions predisposing to hypoxia.
  • Hypoglycemia monitoring: especially when used with insulin or sulfonylureas.
  • Pregnancy and lactation: discuss risks and benefits with a healthcare provider.
  • Drug interaction review: assess concomitant medications for additive effects.
  • Store at ambient temperature: keep in the original pack, protect from moisture.

Avoid Interactions

Metformina + Sitagliptina Blixie can interact with several drug classes; awareness helps prevent adverse events.

Major Interactions (Avoid)

  • Insulin or sulfonylureas: increased risk of severe hypoglycemia.
  • Iodinated contrast agents: may precipitate lactic acidosis in renal‑impaired patients.
  • Strong CYP2C8 inhibitors (e.g., gemfibrozil): may raise metformin plasma levels.

Moderate Interactions (Monitor Closely)

  • Diuretics: can affect renal clearance of metformin.
  • ACE inhibitors or ARBs: may further reduce renal function.
  • Beta‑blockers: may mask hypoglycemia symptoms.
  • Oral corticosteroids: may increase blood glucose, requiring dose adjustment.

Frequently Asked Questions

Metformina + Sitagliptina Blixie is a fixed‑dose oral combination of metformin hydrochloride and sitagliptin indicated to improve glycemic control in adults with type 2 diabetes mellitus when diet, exercise, and monotherapy are insufficient.

Metformin hydrochloride reduces hepatic glucose production and enhances peripheral insulin sensitivity, thereby lowering fasting plasma glucose and contributing to overall glycemic control.

The prescribed dose is determined by the treating healthcare professional based on the patient’s clinical condition, renal function, and response to therapy. No specific dosing regimen is provided here.

Safety in pregnancy and lactation has not been fully established. Women who are pregnant, planning pregnancy, or breastfeeding should discuss potential risks and benefits with their healthcare provider before using this medication.

To place an order, submit an enquiry on the product page at gnhindia.com indicating the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with metformin alone, the addition of sitagliptin provides complementary glucose‑lowering via incretin enhancement, often resulting in greater HbA1c reduction. Unlike sulfonylureas, the combination has a lower intrinsic risk of hypoglycemia when used without insulin.

Store the tablets at ambient temperature, below 25 °C, in the original container, protected from moisture and direct sunlight. Do not use if the packaging is damaged or the tablets appear discolored.

The medication is taken orally, usually with meals to reduce gastrointestinal discomfort. Patients should swallow the tablet whole with a glass of water and follow the dosing schedule prescribed by their clinician.

The most serious adverse events include lactic acidosis, severe hypoglycemia (especially when combined with insulin or sulfonylureas), and acute pancreatitis. Prompt medical attention is required if any of these conditions are suspected.

Patients with severe renal impairment (eGFR < 30 mL/min/1.73 m²), known hypersensitivity to metformin or sitagliptin, a history of lactic acidosis, or acute pancreatitis should avoid this medication. Contra‑indications must be confirmed by a qualified healthcare professional.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Metformin Hydrochloride, Sitagliptin

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT